Stereochemical Identity of a Single Fluorosugar Enables Noninvasive Dual-Biomarker Fingerprinting of Cancer
En palabras de los autores
Abstract Clinical molecular imaging of cancer largely relies on single biomarker-attributable readouts. Through an efficient trapping mechanism, 2-[18F]FDG robustly links PET readouts to the Warburg effect, illuminating only a single metabolic axis within the multichannel biochemical network of cancer. The versatile chemical space of synthetic fluorosugars, however, may offer an attractive framework for broadening the repertoire of metabolic markers accessible to noninvasive imaging. Here, we report Fluorine Metabolic Imaging (FMI), a molecular MRI strategy for simultaneous in vivo mapping of two metabolic biomarkers using a single probe. FMI exploits the altered biochemistry of 3-fluoro-3-deoxy-d-galactose (3FDGal), which undergoes orthogonal intracellular redox transformations mediated by ALDH1A1 and AKR1B1, each yielding a stably trapped fluorine-labeled metabolite with a characteristic 19F-NMR peak. Concurrently mapped by 19F-MRI, these two enzyme-attributable readouts enable noninvasive spatially resolved dual-biomarker visualization. We establish the trapping mechanism of 3FDGal and its enzymatic basis, demonstrating that 3FDGal-initiated fingerprints reflect dual-biomarker variations across different cancer cells. In vivo, FMI distinguishes tumors with contrasting metabolic phenotypes, herein demonstrated in human xenografts not detectable by the canonical 2-[18F]FDG-PET approach. Establishing this proof-of-concept platform for noninvasive multilayered tumor subtyping, FMI with fluorosugars extends metabolic imaging beyond the Warburg scheme into unexplored dimensions of cancer diagnostics.
Apareció: jueves, 19 de noviembre. Journal of the American Chemical Society. Revista con revisión por pares.
DOI: 10.1021/jacs.6c16535